- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 128608, 9 pages
Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies
Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610-0278, USA
Received 2 May 2011; Revised 3 July 2011; Accepted 5 July 2011
Academic Editor: Arkadiusz Dudek
Copyright © 2012 Angelica Trujillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. J. Jabbour, E. Estey, and H. M. Kantarjian, “Adult acute myeloid leukemia,” Mayo Clinic Proceedings, vol. 81, no. 2, pp. 247–260, 2006.
- B. Lowenberg, J. R. Downing, and A. Burnett, “Acute myeloid leukemia,” The New England Journal of Medicine, vol. 341, no. 14, pp. 1051–1062, 1999.
- F. R. Appelbaum, H. Gundacker, D. R. Head et al., “Age and acute myeloid leukemia,” Blood, vol. 107, no. 9, pp. 3481–3485, 2006.
- J. Hoggatt and L. M. Pelus, “Mobilization of hematopoetic stem cells from the bone marrow niche to the blood compartment,” Stem Cell Research and Therapy, vol. 2, no. 2, p. 13, 14.
- F. Ayala, R. Dewar, M. Kieran, and R. Kalluri, “Contribution of bone microenvironment to leukemogenesis and leukemia progression,” Leukemia, vol. 23, pp. 2233–2241, 2009.
- W. Fiedler, U. Graeven, S. Ergün et al., “Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia,” Blood, vol. 89, no. 6, pp. 1870–1875, 1997.
- J. W. Hussong, G. M. Rodgers, and P. J. Shami, “Evidence of increased angiogenesis in patients with acute myeloid leukemia,” Blood, vol. 95, no. 1, pp. 309–313, 2000.
- T. T. F. Shih, H. A. Hou, C. Y. Liu et al., “Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival,” Blood, vol. 113, no. 14, pp. 3161–3167, 2009.
- T. Padro, R. M. Mesters, R. Bieker et al., “Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia,” Blood, vol. 95, no. 8, pp. 2637–2644, 2000.
- I. Kuzu, M. Beksac, M. Arat, H. Celebi, A. H. Elhan, and S. Erekul, “Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival,” Leukemia and Lymphoma, vol. 45, no. 6, pp. 1185–1190, 2004.
- J. L. Liesveld, K. E. Rosell, C. Lu et al., “Acute myelogenous leukemia-microenvironment interactions: role of endothelial cells and proteasome inhibition,” Hematology, vol. 10, no. 6, pp. 483–494, 2005.
- K. Hatfield, A. M. Øyan, E. Ersvaer et al., “Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators,” British Journal of Haematology, vol. 144, no. 1, pp. 53–68, 2009.
- R. C. Kruizinga, H. J. de Jonge, K. R. Kampen, A. M. Walenkamp, and E. S. de Bont, “Vascular endothelial growth factor a isoform mRNA expression in pediatric acute myeloid leukemia,” Pediatric Blood and Cancer, vol. 56, no. 2, pp. 294–297, 2011.
- A. R. Perez, S. E. Sallan, U. Tedrow, S. Connors, E. Allred, and J. Folkman, “Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia,” American Journal of Pathology, vol. 150, no. 3, pp. 815–821, 1997.
- G. J. Madlambayan, A. M. Meacham, K. Hosaka et al., “Leukemia regression by vascular disruption and antiangiogenic therapy,” Blood, vol. 116, no. 9, pp. 1539–1547, 2010.
- W. Hou, W. C. Chou, L. I. Lin et al., “Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia,” Leukemia Research, vol. 32, no. 6, pp. 904–912, 2008.
- S. Loges, G. Heil, M. Bruweleit et al., “Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1109–1117, 2005.
- S. Mourah, R. Porcher, G. Lescaille et al., “Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia,” International Journal of Biological Markers, vol. 24, no. 1, pp. 22–31, 2009.
- T. Padro, R. Bieker, S. Ruiz et al., “Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia,” Leukemia, vol. 16, no. 7, pp. 1302–1310, 2002.
- S. Dias, K. Hattori, Z. Zhu et al., “Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration,” Journal of Clinical Investigation, vol. 106, no. 4, pp. 511–521, 2000.
- M. Wakabayashi, H. Miwa, M. Shikami et al., “Autocrine pathway of angiopoietins-Tie2 system in AML cells,” The Hematology Journal, vol. 5, no. 4, pp. 353–360, 2004.
- H. Reikvam, K. J. Hatfield, P. Lassalle, A. Olsnes Kittang, E. Ersvær, and Ø. Bruserud, “Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release,” Expert Opinion on Investigational Drugs, vol. 19, no. 2, pp. 169–183, 2010.
- C. Morrissey, A. Dowell, T. D. Koreckij et al., “Inhibition of angiopoietin-2 in Lucap 23.1 prostate cancer tumors decreases tumor growth and viability,” The Prostate, vol. 70, no. 16, pp. 1799–1808, 2010.
- A. M. Skinner, D. C. Goldman, A. McBeth, M. J. Shurtleff, H. W. Fleming, and P. Kurre, “Hematopoeitic cells undergo homotypic cell fusion: a novel platform to study genomic instability in leukemogenesis,” in The American Society of Hematology, Orange County Convention Center, Orlando, Fla, USA, 2010.
- C. Lancrin, P. Sroczynska, A. G. Serrano et al., “Blood cell generation from the hemangioblast,” Journal of Molecular Medicine, vol. 88, no. 2, pp. 167–172, 2010.
- A. Bailey, H. Willenbring, S. Jiang et al., “Myeloid lineage progenitors give rise to vascular endothelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13156–13161, 2006.
- C. R. Cogle, D. A. Wainman, M. L. Jorgensen, S. M. Guthrie, R. N. Mames, and E. W. Scott, “Adult human hematopoietic cells provide functional hemangioblast activity,” Blood, vol. 103, no. 1, pp. 133–135, 2004.
- C. R. Cogle and E. W. Scott, “The hemangioblast: cradle to clinic,” Experimental Hematology, vol. 32, no. 10, pp. 885–890, 2004.
- M. B. Grant, W. S. May, S. Caballero et al., “Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization,” Nature Medicine, vol. 8, no. 6, pp. 607–612, 2002.
- A. S. Bailey, S. Jiang, M. Afentoulis et al., “Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells,” Blood, vol. 103, no. 1, pp. 13–19, 2004.
- B. Fang, C. Zheng, L. Liao et al., “Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics,” Blood, vol. 105, no. 7, pp. 2733–2740, 2005.
- M. C. Yoder, L. E. Mead, D. Prater et al., “Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals,” Blood, vol. 109, no. 5, pp. 1801–1809, 2007.
- J. Otten, A. Schultze, P. Schafhausen et al., “Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative,” British Journal of Haematology, vol. 142, no. 1, pp. 115–118, 2008.
- J. Karp, I. Gojo, R. Pili et al., “Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab,” Clinical Cancer Research, vol. 10, no. 11, pp. 3577–3585, 2004.
- R. M. Mesters, L. Zahiragic, C. Schliemann et al., “Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity,” Leukemia, vol. 21, no. 6, pp. 1310–1312, 2007.
- A. C. Lockhart, M. L. Rothenberg, J. Dupont et al., “Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 207–214, 2010.
- W. Fiedler, H. Serve, H. Dohner et al., “A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease,” Blood, vol. 105, no. 3, pp. 986–993, 2005.
- W. Fiedler, R. Mesters, H. Tinnefeld et al., “A phase 2 clinical study of SU5416,” Blood, vol. 102, no. 8, pp. 2763–2767, 2003.
- F. Ravandi, J. E. Cortes, D. Jones et al., “Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1856–1862, 2010.
- S. K. Metzelder, E. Wollmer, A. Neubauer, and A. Burchert, “Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option,” Deutsche Medizinische Wochenschrift, vol. 135, no. 38, pp. 1852–1856, 2010.
- E. Chan, D. Mulkerin, M. Rothenberg et al., “A phase I trial of CEP gemcitabine in patients with advanced adenocarcinoma of the pancreas,” Investigational New Drugs, vol. 26, no. 3, pp. 241–247, 2008.
- F. J. Giles, W. T. Bellamy, Z. Estrov et al., “The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),” Leukemia Research, vol. 30, no. 7, pp. 801–811, 2006.
- G. J. Roboz, F. J. Giles, A. F. List et al., “Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome,” Leukemia, vol. 20, no. 6, pp. 952–957, 2006.
- I. Petit, M. A. Karajannis, V. Loit et al., “The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death,” Blood, vol. 111, no. 4, pp. 1951–1961, 2008.
- J. Tol and C. J. Punt, “Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review,” Clinical Therapeutics, vol. 32, no. 3, pp. 437–453, 2010.
- D. Lal, J. A. Park, J. Marinaro et al., “Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models,” Molecular Cancer Therapeutics, vol. 9, no. 10, pp. 2737–2751, 2010.
- T. Batchelor, D. G. Duda, E. di Tomaso et al., “Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 17, pp. 2817–2823, 2010.
- G. Goss, F. A. Shepherd, S. Laurie et al., “A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group,” European Journal of Cancer, vol. 45, no. 5, pp. 782–788, 2009.
- B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007.
- L. Rimassa and A. Santoro, “Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial,” Expert Review of Anticancer Therapy, vol. 9, no. 6, pp. 739–745, 2009.
- T. T. Shih, H. A. Hou, C. Y. Liu et al., “Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival,” Blood, vol. 113, no. 14, pp. 3161–3167, 2009.
- B. B. Chen, C.-Y. Hsu, C.-W. Yu et al., “Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission,” Radiology, vol. 258, no. 3, pp. 821–831, 2011.